Advancements in uncovering the underlying pathogenesis of myelodysplastic syndrome (MDS) have led to the development of investigational therapies f......READ MORE
The US Food and Drug Administration approval of lower-intensity treatments, including hypomethylating agents (HMAs) and targeted and/or immunomodul......READ MORE
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are part of a disease spectrum that is beginning to enter into the precision medici......READ MORE
Mutations in FLT3 and IDH1/IDH2 are among those that are currently actionable in acute myeloid leukemia (AML). Trials of novel agents and combinati......READ MORE
